Dancing on the edge?

  • Objective Although recreational use of gamma-hydroxybutyrate (GHB) and its precursors gamma-butyrolactone (GBL) and 1,4-butanediol (BD) is increasing and poses high risks (e.g. overdose, addiction, withdrawal), research on motives driving their use is lacking. The present study therefore aims to systematically examine the underlying motives and associations with psychological distress. Method This mixed-methods longitudinal study includes two waves of anonymous online data collection (11/2022–01/2023; 11/2023–01/2024) in Germany. The adult sample (Nbaseline = 2196; with nfollow-up = 240) was recruited via convenience-sampling, primarily from Berlin’s nightlife-scene, and comprises GHB/GBL/BD users and their non-using peers. Structured motive ratings and open-ended self-reported motives were analyzed quantitatively and qualitatively. Cross-lagged panel-models were used to test bidirectional longitudinal associations between GHB/GBL/BD use and anxiety and depressive symptoms, while moderation analyses were used to assess whetherObjective Although recreational use of gamma-hydroxybutyrate (GHB) and its precursors gamma-butyrolactone (GBL) and 1,4-butanediol (BD) is increasing and poses high risks (e.g. overdose, addiction, withdrawal), research on motives driving their use is lacking. The present study therefore aims to systematically examine the underlying motives and associations with psychological distress. Method This mixed-methods longitudinal study includes two waves of anonymous online data collection (11/2022–01/2023; 11/2023–01/2024) in Germany. The adult sample (Nbaseline = 2196; with nfollow-up = 240) was recruited via convenience-sampling, primarily from Berlin’s nightlife-scene, and comprises GHB/GBL/BD users and their non-using peers. Structured motive ratings and open-ended self-reported motives were analyzed quantitatively and qualitatively. Cross-lagged panel-models were used to test bidirectional longitudinal associations between GHB/GBL/BD use and anxiety and depressive symptoms, while moderation analyses were used to assess whether coping motives influenced these relationships. Results GHB/GBL/BD use was primarily driven by hedonistic motives such as euphoria and sexual stimulation, while coping-related motives (e.g. anxiety reduction, mood improvement) were also endorsed, particularly among heavy users. Motives remained largely stable over time. Anxiety and depressive symptoms did not predict later use, nor vice versa. However, coping motives moderated the relationship, strengthening the association between symptoms and use frequency. Conclusions While GHB/GBL/BD are mainly used for recreational hedonistic purposes, distress-related motives also seem to play a role, especially in heavier use. These findings highlight the need for targeted prevention, harm-reduction, and therapeutic strategies that consider both hedonistic and coping-driven use, while accounting for the unique characteristics and risks associated with GHB/GBL/BD.zeige mehrzeige weniger

Metadaten exportieren

Weitere Dienste

Suche bei Google Scholar
Metadaten
Verfasserangaben:Antonia BendauORCID, Lukas Roediger, Rüdiger Schmolke, Moritz Bruno Petzold, Twyla Michnevich, Felix BetzlerORCID
DOI:https://doi.org/10.1080/16066359.2025.2605963
ISSN:1606-6359
ISSN:1476-7392
Titel des übergeordneten Werkes (Englisch):Addiction research and theory
Untertitel (Englisch):The motivational drivers of gamma-hydroxybutyrate/gamma-butyrolactone use – A longitudinal mixed-methods study
Verlag:Routledge, Taylor & Francis
Verlagsort:London
Dokumentart:Wissenschaftlicher Artikel
Sprache:Englisch
Jahr der Erstveröffentlichung:2025
Veröffentlichende Institution:Fachhochschule Potsdam
Datum der Freischaltung:11.03.2026
GND-Schlagwort:Drogenabhängigkeit; Drogenmissbrauch; Hydroxybuttersäure <gamma->
Seitenzahl:16
Fachbereiche und Zentrale Einrichtungen:FB1 Sozial- und Bildungswissenschaften
DDC-Klassifikation:300 Sozialwissenschaften / 360 Soziale Probleme, Sozialdienste
600 Technik, Medizin, angewandte Wissenschaften / 610 Medizin und Gesundheit
Open Access:Hybrid Open Access
Lizenz (Deutsch): Creative Commons - CC BY - Namensnennung 4.0 International
Einverstanden ✔
Diese Webseite verwendet technisch erforderliche Session-Cookies. Durch die weitere Nutzung der Webseite stimmen Sie diesem zu. Unsere Datenschutzerklärung finden Sie hier.